The 36-month beta value for QLGN is at -0.71. Analysts have varying views on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for QLGN is 24.81M, and currently, shorts hold a 0.44% of that float. The average trading volume for QLGN on November 04, 2024 was 2.80M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
QLGN) stock’s latest price update
Qualigen Therapeutics Inc (NASDAQ: QLGN) has seen a decline in its stock price by -7.88 in relation to its previous close of 0.10. However, the company has experienced a -19.21% decline in its stock price over the last five trading sessions. globenewswire.com reported 2024-11-01 that CARLSBAD, Calif., Nov. 01, 2024 (GLOBE NEWSWIRE) — Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) announced today that it will implement a 1-for-50 reverse stock split of the issued shares of its common stock (the “Reverse Stock Split”), effective at 12:01 a.m. Eastern time on November 5, 2024. The Company’s common stock is expected to begin trading on a split-adjusted basis when the market opens on Tuesday, November 5, 2024, and will continue to trade on The Nasdaq Capital Market under the symbol “QLGN.” The new CUSIP number for the common stock will be 74754R 301.
QLGN’s Market Performance
Qualigen Therapeutics Inc (QLGN) has experienced a -19.21% fall in stock performance for the past week, with a -45.23% drop in the past month, and a -56.08% drop in the past quarter. The volatility ratio for the week is 14.12%, and the volatility levels for the past 30 days are at 20.68% for QLGN. The simple moving average for the past 20 days is -36.37% for QLGN’s stock, with a -68.00% simple moving average for the past 200 days.
QLGN Trading at -43.43% from the 50-Day Moving Average
After a stumble in the market that brought QLGN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -88.42% of loss for the given period.
Volatility was left at 20.68%, however, over the last 30 days, the volatility rate increased by 14.12%, as shares sank -45.43% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -54.37% lower at present.
During the last 5 trading sessions, QLGN fell by -17.56%, which changed the moving average for the period of 200-days by -81.57% in comparison to the 20-day moving average, which settled at $0.1426. In addition, Qualigen Therapeutics Inc saw -83.52% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for QLGN
Current profitability levels for the company are sitting at:
- -1.03 for the present operating margin
- 0.16 for the gross margin
The net margin for Qualigen Therapeutics Inc stands at -1.21. The total capital return value is set at 1.92. Equity return is now at value -1656.23, with -134.07 for asset returns.
Based on Qualigen Therapeutics Inc (QLGN), the company’s capital structure generated -0.64 points at debt to capital in total, while cash flow to debt ratio is standing at -4.19. The debt to equity ratio resting at -0.39. The interest coverage ratio of the stock is -8.18.
Currently, EBITDA for the company is -11.3 million with net debt to EBITDA at -0.19. When we switch over and look at the enterprise to sales, we see a ratio of 0.5. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.11.
Conclusion
In conclusion, Qualigen Therapeutics Inc (QLGN) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
